Mantle cell lymphoma

MCL is a mature B-cell lymphoma, usually associated with cyclin D1 overexpression and an IGH::CCND1 rearrangement. Tissue, immune markers and genetics are interpreted together; uncommon cyclin-D1-negative disease needs expert assessment. A blood or marrow presentation does not make it a different leukemia by default.

Blastoid or pleomorphic morphology, a high Ki-67 proliferation index and TP53 abnormalities identify important risk. MIPI describes clinical risk, while biological findings refine it. Ask whether TP53 mutation testing was performed; p53 staining is not a fully interchangeable test.

Assessment commonly includes imaging, blood counts, LDH and marrow evaluation when relevant. Gastrointestinal involvement is possible; endoscopy is selected according to symptoms and whether the result changes staging or a local-treatment plan. Limited-stage disease is uncommon and needs careful confirmation.

Some asymptomatic low-burden cases, including selected leukemic non-nodal presentations, can begin with observation. This requires stable blood counts, no threatened organ and planned reassessment. A low-volume appearance cannot overrule aggressive biology or concerning symptoms.

Cytarabine-containing immunochemotherapy with a BTK inhibitor has changed the first-line landscape. TRIANGLE studied adults aged 18–65 and compared strategies with and without autologous transplantation. Its extended follow-up supports an ibrutinib-containing pathway without routine transplantation for appropriate patients.

The EBMT cellular-therapy recommendations allow omission of first-line autologous transplantation at least in standard-risk situations with the relevant BTK-containing induction and/or sufficiently deep MRD clearance. This is a protocol-based decision, not permission to omit any part of any regimen after one negative blood result.

High-risk biology, inability to obtain a BTK inhibitor and differences in treatment response still require individual discussion. Maintenance is part of many pathways and should be planned alongside induction, rather than treated as an afterthought.

Bendamustine–rituximab is a common backbone. The US authorizes acalabrutinib with bendamustine and rituximab for untreated adults ineligible for autologous transplantation. Fitness, infections, blood counts and drug interactions matter when adding prolonged targeted therapy.

ENRICH tested chemotherapy-free ibrutinib–rituximab against immunochemotherapy in patients aged at least 60. It supports a chemotherapy-free option, but the benefit differed by comparator: the bendamustine–rituximab subgroup did not show the same clear superiority seen against R-CHOP. Trial evidence and local licensing must both be checked.

TP53-mutated disease often responds poorly to conventional chemotherapy-based strategies. Early specialist and trial review is valuable. This does not mean treatment cannot work; it means that simply escalating the familiar chemotherapy pathway may not solve the biological problem.

A phase II study of zanubrutinib, obinutuzumab and venetoclax showed encouraging activity in untreated TP53-mutated MCL. Other studies, including CHESS, explore targeted induction and reduced chemotherapy. These populations and study designs differ; they do not establish every such combination as universally approved first-line care.

If a covalent BTK inhibitor has not been used, an appropriate agent may be an important relapse option. Stopping because of intolerance differs from progression despite treatment: switching within the same class can address some toxicity problems but should not be assumed to overcome established resistance.

Pirtobrutinib, a noncovalent BTK inhibitor, has a US MCL indication after at least two systemic lines including a BTK inhibitor. Sonrotoclax, a BCL-2 inhibitor, received US accelerated approval for the same broad prior-line setting; its evidence came from a single-arm study rather than a direct comparison with CAR-T.

BCL-2 treatment can cause tumor lysis and requires a supervised initiation plan. At progression on BTK therapy, coordinate the next treatment promptly rather than stopping without a bridge when disease is active.

Brexucabtagene autoleucel and lisocabtagene maraleucel are CD19 CAR-T options with product- and country-specific eligibility. The US Tecartus MCL indication is broader than its European prior-treatment wording; the US Breyanzi MCL indication requires at least two prior lines including a BTK inhibitor.

Assessment covers disease control during manufacturing, T-cell collection, organ function, infection and caregiver support. CRS, neurological toxicity, prolonged low counts and infection require specialized monitoring. CAR-T in first-line high-risk MCL remains investigational, not a routine substitute for all other care.

Allogeneic transplantation is a separate donor-cell strategy with graft-versus-host and nonrelapse risks. It may be considered in selected later-line situations, particularly after cellular-therapy failure or when alternatives are unavailable.

Imaging, examination, blood and sometimes marrow tests assess response. MRD is increasingly informative, but its use depends on assay sensitivity, sample and the exact treatment strategy. A negative result at one sensitivity is not interchangeable with a deeper assay or a different protocol.

Monitoring also tracks infections, bleeding, heart rhythm and drug interactions with BTK inhibitors, as well as immune recovery after antibodies or cellular therapy. Bring anticoagulants, supplements and all other medicines to each treatment review.

Bring pathology, Ki-67 and TP53 results, imaging, prior BTK-inhibitor names and reasons for stopping, remission durations, MRD reports with sensitivity and transplant history. A second opinion should distinguish resistance from intolerance and identify which option must be prepared before the current treatment fails.

For care in another country, confirm the actual product label, manufacturing access and follow-up plan. A trial result or regulatory approval does not establish that a particular hospital can provide the treatment for every patient.